JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
Alexandra Dusa(Ludwig Cancer Research), Stefan N. Constantinescu(Ludwig Cancer Research)
Cited by 85
Related Papers
JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation
|Journal of Biological Chemistry|2005|162
Orientation‐specific signalling by thrombopoietin receptor dimers
|The EMBO Journal|2011|89
Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2
|Journal of Biological Chemistry|2008|64
Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix
|Biochemical Journal|2016|41
Signal transduction molecule patterns indicating potential glioblastoma therapy approaches
|OncoTargets and Therapy|2013|27